Clinical Radiology
Volume 63, Issue 3 , Pages 241-251 , March 2008

The role of hybrid SPECT-CT in oncology: current and emerging clinical applications

  • F.U. Chowdhury
    • ,
  • A.F. Scarsbrook

      Affiliations

    • Corresponding Author InformationGuarantor and correspondent: A.F. Scarsbrook, Consultant Radiologist & Nuclear Medicine Physician, Departments of Radiology & Nuclear Medicine, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK. Tel.: +44 0113 206 4047; fax: +44 0113 206 4691.

Received 8 October 2007 ,Revised 13 November 2007 ,Accepted 18 November 2007.

References 

  1. von Schulthess GK, Pelc NJ. Integrated-modality imaging: the best of both worlds. Acad Radiol. 2002;9:1241–1244
  2. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr. 1992;16:620–633
  3. Pietrzyk U, Herholz K, Fink G, et al. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med. 1994;35:2011–2018
  4. Hasegawa BH, Gingold EL, Reilly SM, et al. Description of a simultaneous emission-transmission CT system. Proc Soc Photo Instrum Eng. 1990;1231:50–60
  5. Bocher M, Balan A, Krausz Y, et al. Gamma camera-mounted anatomical x-ray tomography: technology, system characteristics and first images. Eur J Nucl Med Mol Imaging. 2000;27:619–627
  6. Patton JA, Delbeke D, Sandler MP. Image fusion using an integrated dual-head coincidence camera with x-ray tube based attenuation maps. J Nucl Med. 2000;41:1364–1368
  7. Israel O, Keidar Z, Iosilevsky G, et al. The fusion of anatomic and physiologic imaging in the management of patients with cancer. Semin Nucl Med. 2001;31:191–205
  8. Hasegawa BH, Iwata K, Wong KH, et al. Dual-modality imaging of function and physiology. Acad Radiol. 2002;9:1305–1321
  9. Hasegawa BH, Wong KH, Iwata K, et al. Dual-modality imaging of cancer with SPECT/CT. Technol Cancer Res Treat. 2002;1:449–458
  10. Keidar Z, Israel O, Krausz Y. SPECT/CT in tumour imaging: technical aspects and clinical applications. Semin Nucl Med. 2003;33:205–218
  11. Scillachi O, Simonetti G. Fusion imaging in nuclear medicine—applications of dual-modality systems in oncology. Cancer Biother Radiopharm. 2004;19:1–10
  12. Beyer T, Townsend DW, Brun T, et al. A combined PET-CT scanner for clinical oncology. J Nucl Med. 2000;41:1369–1379
  13. Hany TF, Steinert HC, Goerres GW, et al. Improvement of diagnostic accuracy of PET imaging using an in-line PET-CT system: initial results. Radiology. 2002;225:575–581
  14. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405–422
  15. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360–385
  16. Schillaci O, Danieli R, Manni C, et al. Is SPECT/CT with a hybrid camera useful to improve scintigraphic imaging interpretation?. Nucl Med Commun. 2004;7:705–710
  17. Schillaci O. Hybrid SPECT/CT: a new era for SPECT imaging?. Eur J Nucl Med Mol Imaging. 2005;32:521–524
  18. Roach PJ, Schembri GP, Ho Shon IA, et al. SPECT/CT imaging using a spiral CT scanner for anatomical localization: impact on diagnostic accuracy and reporter confidence in clinical practice. Nucl Med Commun. 2006;27:977–987
  19. O'Connor MK, Kemp BJ. Single-photon emission computed tomography/computed tomography: basic instrumentation and innovations. Semin Nucl Med. 2006;36:258–266
  20. Oberg K. Management of neuroendocrine tumours. Ann Oncol. 2004;15:iv293–iv298
  21. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–247
  22. Reubi JC, Laissue J, Krenning EP, et al. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implication. J Steroid Biochem Mol Biol. 1992;43:27–35
  23. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  24. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32:84–91
  25. Schillaci O. Functional-anatomical image fusion in neuroendocrine tumours. Cancer Biother Radiopharm. 2004;19:129–134
  26. Even-Sapir E, Keidar Z, Sachs J, et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med. 2001;42:998–1004
  27. Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol. 2003;59:565–573
  28. Pfannenberg AC, Eschmann SM, Horger M, et al. Benefit of anatomical–functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2003;30:835–843
  29. Hillel PG, van Beek EJR, Taylor C, et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours. Clin Radiol. 2006;61:579–587
  30. Shapiro B, Sisson JC, Shulkin BL. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuroendocrine tumors. Q J Nucl Med. 1995;39:3–8
  31. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998;39:679–688
  32. Ozer S, Dobrozemsky G, Kienast O, et al. Value of combined XCT/SPECT technology for avoiding false positive planar (123)I-MIBG scintigraphy. Nuklearmedizin. 2004;43:164–170
  33. Lairmore TC, Wells SA. Medullary carcinoma of the thyroid: current diagnosis and management. Semin Surg Oncol. 1991;7:92–99
  34. Intenzo CM, Jabbour S, Lin HC, et al. Scintigraphic imaging of body neuroendocrine tumors. RadioGraphics. 2007;27:1355–1369
  35. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306
  36. Shapiro B, Rufini V, Jarwan A, et al. Artifacts, anatomical and physiological variants, and unrelated diseases that may cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med. 2000;30:115–132
  37. Yamamoto Y, Nishiyama Y, Monden T, et al. Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma. J Nucl Med. 2003;44:1905–1910
  38. Tharp K, Israel O, Hausmann J, et al. Impact of 131I-SPECT-CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:1435–1442
  39. Ruf J, Lehmkuhl L, Bertram H, et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun. 2004;25:1177–1182
  40. Front D, Bar-Shalom R, Israel O. The continuing role of gallium 67 scintigraphy in the age of receptor imaging. Semin Nucl Med. 1997;27:68–74
  41. Even-Sapir E, Israel O. Gallium-67: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging. 2003;30:S65–S81
  42. Bar-Shalom R. Gallium SPECT/CT in lymphoma: the ups and downs of functional imaging. Eur J Nucl Med Mol Imaging. 2005;32:1247–1249
  43. Chajari M, Lacroix J, Peny AM, et al. Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?. Eur J Nucl Med Mol Imaging. 2002;29:380–387
  44. Palumbo B, Sivolella S, Palumbo I, et al. 67Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma. Eur J Nucl Med Mol Imaging. 2005;32:1011–1017
  45. Israel O, Keider Z, Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med. 2004;34:166–179
  46. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med. 2006;47:1326–1334
  47. Kirby AM, Mikhaeel NG. The role of FDG PET in the management of lymphoma: what is the evidence base?. Nucl Med Commun. 2007;28:335–354
  48. Alazraki N, Glass EC, Castronovo F, et al. Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel node localisation in melanoma of intermediate thickness 1.0. J Nucl Med. 2002;43:1414–1418
  49. Alazraki N, Styblo T, Grant SE, et al. Sentinel node staging of early breast cancer using lymphoscintigraphy and the intraoperative gamma-detecting probe. Semin Nucl Med. 2000;1:56–64
  50. Alex JC, Sasaki CT, Krag DN, et al. Sentinel lymph node radiolocalization in head and neck squamous cell carcinoma. Laryngoscope. 2000;198–203
  51. Jansen L, Niewag OE, Peterse JL, et al. Reliability of sentinel node biopsy for staging melanoma. Br J Surgery. 2000;87:484–489
  52. Colnot DR, Nieuwenhuis EJ, van den Brekel MW, et al. Head and neck squamous cell carcinoma: US-guided fine-needle aspiration of sentinel lymph nodes for improved staging-initial experience. Radiology. 2001;218:289–293
  53. Even-Sapir E, Lerman H, Lievshitz G, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med. 2003;44:1413–1420
  54. Husarik DB, Steinert HC. Single-photon emission computed tomography/computed tomography for sentinel node mapping in breast cancer. Semin Nucl Med. 2007;37:29–33
  55. Wagner A, Schicho K, Glaser C, et al. SPECT-CT for tomographic mapping of sentinel lymph nodes prior to gamma probe-guided biopsy in head and neck squamous cell carcinoma. J Craniomaxillofac Surg. 2004;32:343–349
  56. Sherif A, Garske U, de La Torre M, et al. Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancer. Eur Urol. 2006;50:83–91
  57. Krengli M, Ballare A, Cannillo B, et al. Potential advantage of studying the lymphatic drainage by sentinel node technique and SPECT-CT image fusion for pelvic irradiation of prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:1100–1104
  58. Stoker DJ, Saifuddin A. Bone tumours: malignant lesions. In:  Grainger RG,  Allison DJ,  Adam A,  Dixon AK editor. Diagnostic radiology. 3rd ed.. London: Harcourt Publishers Ltd; 2002;p. 1869–1900
  59. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic and hybrid modalities. J Nucl Med. 2005;46:1356–1367
  60. Horger M, Eschmann SM, Pfannenberg C, et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR Am J Roentgenol. 2004;183:655–661
  61. Reinartz P, Schaffeldt J, Sabri O, et al. Benign versus malignant osseous lesions in the lumbar vertebrae: differentiation by means of bone SPET. Eur J Nucl Med. 2000;27:721–726
  62. Horger M, Bares R. The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease. Semin Nucl Med. 2006;36:286–294
  63. Utsonomiya D, Shiraishi S, Imuta M, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology. 2006;238:264–271
  64. Romer W, Nömayr A, Uder M, et al. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med. 2006;1102–1106
  65. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592
  66. Polascik TJ, Manyak MJ, Haseman MK, et al. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer. 1999;85:1586–1592
  67. Manyak MJ, Hinkle GH, Olsen JO, et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology. 1999;54:1058–1063
  68. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localised prostate cancer. J Urol. 1999;162:1322–1328
  69. Sodee DB, Nelson AD, Faulhaber PF, et al. Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005;3:230–238
  70. Wong TZ, Turkington TG, Polascik TJ, et al. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol. 2005;184:676–680
  71. National Collaborating Centre for Acute Care . Diagnosis and treatment of lung cancer. London: National Collaborating Centre for Acute Care; 2005;
  72. Swensen SJ, Jett JR, Hartman T, et al. Screening for lung cancer with CT: Mayo Clinic experience. Radiology. 2003;226:756–761
  73. Schillaci O. Single-photon emission computed tomography/computed tomography in lung cancer and malignant lymphoma. Semin Nucl Med. 2006;36:275–285
  74. Sergiacomi G, Schillaci O, Leporace M, et al. Integrated multislice CT and Tc-99m Sestamibi SPECT-CT evaluation of solitary pulmonary nodules. Radiol Med. 2006;111:213–224
  75. Ferran N, Ricart Y, Lopez M. Characterization of radiologically indeterminate lung lesions: 99mTc-depreotide versus 18F-FDG PET. Nucl Med Commun. 2006;27:507–514
  76. Chiti A, Maffioli LS, Infante M, et al. Assessment of mediastinal involvement in lung cancer with technetium-99m-sestamibi SPECT. J Nucl Med. 1996;37:938–942
  77. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual modality PET/CT in preoperative staging. Radiology. 2003;229:526–533
  78. Verhagen AFT, Bootsma GP, Tjan-Heijnen VCG, et al. FDG-PET in staging lung cancer. How does it change the algorithm?. Lung Cancer. 2004;44:175–181
  79. Devaraj A, Cook GJ, Hansell DM. PET/CT in non-small cell lung cancer staging-promises and problems. Clin Radiol. 2007;62:97–108
  80. McKinney PA. Brain tumours: incidence, survival and aetiology. J Neurol Neurosurg Psychiatry. 2004;75:12–17
  81. Kieffer SA, Chang J-K. Intracranial neoplasms. In:  Haaga JR,  Lanzieri CF,  Gilkeson RC editor. CT and MR imaging of the whole body. 4th ed.. Missouri: Mosby; 2003;p. 124–206
  82. Chen W, Silverman DHS, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904–911
  83. Schillaci O, Filippi L, Manni C, et al. Single-photon emission computed tomography/computed tomography in brain tumors. Semin Nucl Med. 2007;37:34–47
  84. Del Soye A, Moncayo R, Tafuni G, et al. Position of nuclear medicine techniques in the diagnostic work-up of brain tumors. Q J Nucl Med Mol Imaging. 2004;48:76–81
  85. Pietrzyk U, Herholz K, Weiss WD. Three-dimensional alignment of functional and morphological tomograms. J Comput Assist Tomogr. 1990;14:51–59
  86. Filippi F, Schillaci O, Santoni R, et al. Usefulness of SPECT/CT with a hybrid camera for the functional anatomical mapping of primary brain tumors by [Tc99m] tetrofosmin. Cancer Biother Radiopharm. 2006;26:41–48
  87. Brans B, Bodei L, Giammarile F, et al. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”. Eur J Nucl Med Mol Imaging. 2007;34:772–786
  88. Prideaux AR, Song H, Hobbs RF, et al. Three-dimensional radiobiologic dosimetry : application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007;48:1008–1016
  89. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–2762
  90. Mansberg R, Sorensen N, Mansberg V, et al. Yttrium 90 Bremsstrahlung SPECT/CT scan demonstrating areas of tracer/tumour uptake. Eur J Nucl Med Mol Imaging. 2007;
  91. Machac J, Weintraub J, Nowakowski FS, et al. Variations in liver perfusion patterns in patients with liver tumors undergoing therapy with yttrium-90 microspheres, studied with SPECT-CT. J Nucl Med. 2007;48(Suppl. 2):396P
  92. Raphael B, Akhurst T, Rao V, et al. Hepatic arterial pump perfusion. The value of macroaggregated albumin (MAA) SPECT/CT in comparison with planar and SPECT imaging. J Nucl Med. 2007;48(Suppl. 2):390P
  93. Juweid ME. Radioimmunotherapy of B-cell non Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002;43:1507–1529
  94. Koral KF, Kasadny KR, Kessler ML, et al. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients. J Nucl Med. 1994;35:1714–1720
  95. Boucek JA, Harvey Turner J. Validation of prospective whole-body bone marrow dosimetry by SPECT-CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2005;32:458–469

PII: S0009-9260(07)00488-6

doi: 10.1016/j.crad.2007.11.008

Clinical Radiology
Volume 63, Issue 3 , Pages 241-251 , March 2008

Article Tools

* Image Usage & Resolution